prkrip1 Antibody

What is PRKRIP1 and why is it important in research?

PRKRIP1 (PRKR Interacting Protein 1, IL11 Inducible) is a protein encoded by the PRKRIP1 gene in humans. It has gained significance in research particularly for its role in chronic kidney disease (CKD). Studies have shown that anti-PRKRIP1 autoantibodies are significantly higher in CKD samples compared to control samples, with approximately 1.3 times increase in level . This protein has a calculated molecular weight of approximately 21 kDa and consists of 184-185 amino acids . Research interest in PRKRIP1 has increased due to its potential as a biomarker in chronic kidney disease and its involvement in protein-protein interactions.

How do I select the appropriate PRKRIP1 antibody for my specific research needs?

When selecting a PRKRIP1 antibody for your research, consider the following methodological approach:

• Define your experimental application: Different antibodies are validated for specific applications like Western Blot (WB), ELISA, Immunohistochemistry (IHC), or Immunofluorescence (IF). Choose an antibody specifically validated for your application .

• Determine species reactivity requirements: PRKRIP1 antibodies vary in their reactivity profiles. Some are specific to human samples only, while others cross-react with mouse, rat, and even other species like cow, dog, and pig .

• Consider clonality based on research needs:

  • Monoclonal antibodies (e.g., clone 4D11-3F11, M2, or 1F6-3C2) offer consistency and specificity for a single epitope

  • Polyclonal antibodies provide broader epitope recognition and potentially stronger signals

• Examine epitope specificity: Antibodies target different regions of PRKRIP1, such as AA 1-185, AA 1-184, or N-terminal regions. Select based on the region of interest for your study .

• Verify antibody validation data: Review the validation data available from manufacturers, including positive controls and recommended working dilutions for specific applications .

What are the typical working dilutions and experimental conditions for PRKRIP1 antibodies?

Working dilutions and conditions vary based on the specific antibody and application:

For storage conditions, most PRKRIP1 antibodies should be:

• Stored at -20°C for long-term stability

• Aliquoted to prevent freeze-thaw cycles

• Typically provided in PBS buffer with 0.09% sodium azide and additional stabilizers like glycerol

How can PRKRIP1 antibodies be utilized in studying chronic kidney disease biomarkers?

PRKRIP1 antibodies have emerged as valuable tools in chronic kidney disease (CKD) research, particularly as potential biomarkers for early detection. A methodological approach includes:

• Biomarker validation studies: Research has shown that anti-PRKRIP1 autoantibodies are significantly elevated in CKD samples (mean 0.17, standard deviation 0.09) compared to control samples (mean 0.13, standard deviation 0.05), representing a 1.3 times increase in level with a t-test p-value of 0.0139 .

• Correlation analysis: Anti-PRKRIP1 levels strongly correlate with anti-angiotensinogen (anti-AGT) levels across samples with chronic renal injury (Pearson correlation 0.47, p-value 0.00056), suggesting potential mechanistic relationships between these biomarkers .

• Biomarker sensitivity and specificity assessment: When evaluating PRKRIP1 as a biomarker, researchers should analyze receiver operating characteristic (ROC) curves. Current studies show anti-AGT demonstrated a sensitivity of 70% at a specificity of 70%, and combining anti-AGT and anti-PRKRIP1 measurements yielded an AUC of 0.73 .

• Longitudinal studies: The current approach involves validating whether these auto-antibodies can provide means to follow the evolution of CKD in patients with early stages of renal insufficiency, and if rising titers correlate with the rate of progression .

• Epitope mapping: Further delineation of the reactive peptides is needed to improve the sensitivity and specificity to above 90%, where performance reaches clinical levels. This involves using different antibodies targeting various regions of PRKRIP1 .

What are the considerations for using PRKRIP1 antibodies in immunoprecipitation experiments?

When designing immunoprecipitation (IP) experiments with PRKRIP1 antibodies, follow these methodological guidelines:

• Antibody selection for IP:

  • Choose antibodies specifically validated for immunoprecipitation

  • Consider using unconjugated antibodies, biotinylated antibodies with streptavidin-bead conjugates, or antibodies directly conjugated to beads

• Lysis buffer optimization:

  • Use appropriate lysis buffers for your specific cell type or tissue

  • Consider whether native or denaturing conditions are required for your research question

• Critical controls:

  • Include an input control (whole lysate) to ensure the western blot portion is working properly

  • Use an isotype control matching the IgG subclass of your primary antibody (e.g., Normal Rabbit IgG for rabbit polyclonal antibodies)

  • Consider a bead-only control if experiencing non-specific binding issues

• Optimized washing and elution:

  • Wash the beads thoroughly to remove nonspecifically bound proteins

  • After centrifugation, remove liquid with a pipette, not vacuum aspiration

  • Use an appropriate elution buffer for your specific experiment

• Analysis options:

  • Western blot analysis: Use the same antibody for detection if also validated for WB, or select a different WB-validated antibody to the target

  • Mass spectrometry: Consider both bottom-up proteomic workflows for peptide sequencing and top-down LC-MS methods to monitor intact mass and post-translational modifications

How can PRKRIP1 antibodies be used in multiplexed immunoassays?

For developing multiplexed immunoassays incorporating PRKRIP1 antibodies, consider this methodological framework:

• Antibody compatibility assessment:

  • Test for cross-reactivity with other antibodies in your multiplex panel

  • Ensure that secondary antibodies do not cross-react with primaries from different species

  • Consider using directly conjugated antibodies to minimize cross-reactivity issues

• Optimization for protein microarrays:

  • When incorporating PRKRIP1 antibodies in protein microarrays, follow established protocols like those used in kidney disease biomarker studies

  • Use blocking buffers containing components like sodium phosphate, NaCl, Triton X-100, glycerol, reduced glutathione, and dithiothreitol at pH 7.4

  • Implement appropriate washing steps with PBST buffer (PBS with 1% bovine serum albumin and 0.1% Tween 20)

• Signal detection optimization:

  • For fluorescence-based detection, use appropriate conjugated secondary antibodies like Alexa Fluor® 647

  • Optimize scanning parameters (PMT gain, laser power, focus point) for microarrays

  • Ensure proper image acquisition and analysis software settings

• Statistical considerations for multiplex data:

  • Calculate spot-to-spot correlation coefficients (e.g., Pearson or Spearman) to assess reproducibility

  • Implement appropriate selection criteria for significant hits (e.g., differential increase in mean intensity ≥ twofold, p-value thresholds)

  • Validate microarray results with orthogonal methods like ELISA

What is the optimal protocol for using PRKRIP1 antibodies in Western blotting?

For optimal Western blotting with PRKRIP1 antibodies, follow this detailed methodological approach:

• Sample preparation:

  • Use appropriate lysis buffers containing protease inhibitors

  • For HeLa cells and mouse heart tissue, which have been validated as positive controls for PRKRIP1 detection , ensure complete lysis and protein solubilization

• Gel electrophoresis and transfer:

  • Use SDS-PAGE gels appropriate for the expected molecular weight of PRKRIP1 (approximately 21 kDa)

  • Ensure complete transfer to PVDF or nitrocellulose membranes

• Blocking and antibody incubation:

  • Block membranes in appropriate blocking buffer (typically 5% non-fat dry milk or BSA in TBST)

  • Dilute primary PRKRIP1 antibodies according to manufacturer recommendations:

    • Typically 1:500-1:3000 for WB applications

    • For the Proteintech antibody (16794-1-AP), the recommended dilution is 1:500-1:3000

    • Incubate overnight at 4°C or 1-2 hours at room temperature

• Washing and secondary antibody:

  • Wash thoroughly with TBST buffer

  • Use appropriate species-specific secondary antibodies conjugated to HRP or fluorescent tags

  • Follow with additional washing steps

• Detection and analysis:

  • Use appropriate detection method (chemiluminescence or fluorescence)

  • Verify specificity by observing a band at approximately 21 kDa, though some PRKRIP1 antibodies detect the protein at slightly different weights (e.g., 50 kDa for PRRC1)

  • Include appropriate positive controls (e.g., HeLa cells, mouse heart tissue)

How should I design immunohistochemistry experiments using PRKRIP1 antibodies?

For immunohistochemistry (IHC) experiments with PRKRIP1 antibodies, follow this methodological framework:

• Tissue preparation and fixation:

  • For paraffin-embedded sections, use appropriate fixation methods (typically 10% neutral buffered formalin)

  • Cut sections to appropriate thickness (typically 4-6 μm)

• Antigen retrieval optimization:

  • PRKRIP1 antibodies often require specific antigen retrieval methods

  • Use TE buffer pH 9.0 as suggested for some antibodies, or alternatively, citrate buffer pH 6.0

  • Optimize time and temperature for your specific tissue and antibody

• Blocking and antibody incubation:

  • Block endogenous peroxidase activity and non-specific binding

  • Dilute PRKRIP1 antibodies according to manufacturer recommendations:

    • Typical dilutions for IHC range from 1:50-1:500

    • For the Sigma Aldrich antibody (HPA051146), the recommended dilution is 1:500-1:1000

    • Optimize incubation time and temperature

• Detection system selection:

  • Choose appropriate detection systems (e.g., HRP-polymer, ABC method)

  • Select chromogens based on experimental needs (e.g., DAB, AEC)

  • Consider counterstaining methods for tissue context

• Controls and validation:

  • Include positive control tissues known to express PRKRIP1

  • For human pancreas tissue, positive IHC staining has been reported

  • Include negative controls (omitting primary antibody) and isotype controls

What are the key considerations for using PRKRIP1 antibodies in ELISA assays?

For developing ELISA assays with PRKRIP1 antibodies, implement this methodological approach:

• ELISA format selection:

  • Direct ELISA: Coat plates with PRKRIP1 protein to detect anti-PRKRIP1 autoantibodies

  • Sandwich ELISA: Use capture and detection antibodies recognizing different PRKRIP1 epitopes

  • Competitive ELISA: For quantitative analysis of PRKRIP1 in complex samples

• Assay optimization parameters:

  • Coating concentration and buffer optimization

  • Blocking buffer selection to minimize background

  • Antibody concentration optimization:

    • For some PRKRIP1 antibodies, ELISA titers of 1:1562500 have been reported

    • Optimize based on your specific antibody and application

• Validation in relevant samples:

  • For CKD research, validate in patient serum samples

  • In one study, anti-PRKRIP1 autoantibodies were detected in serum from 50 patients with renal insufficiency and 21 healthy control individuals

  • Establish standard curves using recombinant PRKRIP1 protein

• Data analysis and interpretation:

  • Calculate sensitivity, specificity, and detection limits

  • For biomarker applications, determine appropriate cutoff values

  • Consider statistical methods to assess correlation with disease status

• Performance metrics from published research:

  • In CKD research, anti-PRKRIP1 autoantibodies showed a 1.3-fold increase in CKD samples vs. controls

  • Mean values: 0.17 (SD 0.09) in CKD vs. 0.13 (SD 0.05) in controls

  • Significant difference with t-test p-value of 0.0139

What are common problems encountered when using PRKRIP1 antibodies and how can they be resolved?

When working with PRKRIP1 antibodies, researchers may encounter several challenges. Here's a methodological approach to troubleshooting:

• High background signal:

  • Cause: Insufficient blocking, excessive antibody concentration, or cross-reactivity

  • Solution:

    • Optimize blocking conditions (time, temperature, blocking agent)

    • Titrate antibody to determine optimal concentration

    • Increase washing steps and duration

    • Consider using different blocking agents (BSA, normal serum, commercial blockers)

• Weak or no signal:

  • Cause: Insufficient antigen, antibody degradation, or incompatible detection method

  • Solution:

    • Verify protein expression in your sample using positive controls

    • Optimize antigen retrieval for IHC applications

    • Ensure proper antibody storage and avoid freeze-thaw cycles

    • Increase antibody concentration or incubation time

    • For Western blots, confirm transfer efficiency

• Non-specific bands in Western blot:

  • Cause: Cross-reactivity, sample degradation, or secondary antibody issues

  • Solution:

    • Use freshly prepared samples with protease inhibitors

    • Optimize antibody concentration

    • Increase washing stringency

    • Consider using a different PRKRIP1 antibody targeting a different epitope

    • Validate with knockout or knockdown controls when possible

• Inconsistent results between experiments:

  • Cause: Variations in technique, reagent quality, or sample handling

  • Solution:

    • Standardize protocols with detailed SOPs

    • Use consistent lots of antibodies when possible

    • Implement rigorous positive and negative controls

    • Monitor and standardize experimental conditions (temperature, incubation times)

• Cross-reactivity with unintended targets:

  • Cause: Antibody binding to proteins with similar epitopes

  • Solution:

    • Validate antibody specificity using techniques like immunoprecipitation followed by mass spectrometry

    • Use multiple antibodies targeting different epitopes to confirm results

    • Include appropriate controls (isotype controls, blocking peptides)

How can I optimize PRKRIP1 antibody performance for detecting low abundance targets?

For detecting low abundance PRKRIP1 in samples, implement these methodological optimizations:

• Sample enrichment strategies:

  • Implement subcellular fractionation to concentrate PRKRIP1

  • Consider immunoprecipitation to enrich PRKRIP1 before detection

  • For tissue samples, use laser capture microdissection to isolate regions of interest

• Signal amplification methods:

  • For IHC/IF: Use tyramide signal amplification (TSA)

  • For Western blot: Consider using enhanced chemiluminescence substrates with longer exposure times

  • For ELISA: Implement biotin-streptavidin amplification systems

• Detection system optimization:

  • Use highly sensitive detection systems (e.g., digital imaging platforms with high dynamic range)

  • For fluorescence applications, use low-background fluorophores and confocal microscopy

  • Adjust gain and sensitivity settings on detection instruments

• Antibody concentration optimization:

  • Perform careful titration experiments to determine optimal antibody concentration

  • Consider longer incubation times (overnight at 4°C) to increase binding efficiency

  • Use high-affinity monoclonal antibodies for specific epitopes

• Noise reduction strategies:

  • Implement rigorous blocking protocols to minimize background

  • Use highly purified antibody preparations

  • Consider using recombinant antibody fragments (e.g., Fab, scFv) for reduced background

  • Remove non-specific binding proteins from samples when possible

What controls should be implemented when validating PRKRIP1 antibody specificity?

For rigorous validation of PRKRIP1 antibody specificity, implement this methodological framework of controls:

• Primary validation controls:

  • Positive tissue/cell controls: Use samples known to express PRKRIP1, such as HeLa cells or mouse heart tissue

  • Negative controls: Include tissues or cells known not to express PRKRIP1

  • Knockdown/knockout validation: Compare staining in wild-type vs. PRKRIP1 knockdown/knockout samples

  • Overexpression validation: Compare staining in cells with and without PRKRIP1 overexpression

• Technical controls for immunostaining:

  • Isotype controls: Use matched isotype antibodies (e.g., rabbit IgG for rabbit anti-PRKRIP1) at the same concentration

  • Absorption controls: Pre-incubate antibody with purified PRKRIP1 protein before staining

  • Secondary antibody only: Omit primary antibody to assess non-specific binding of secondary antibody

• Controls for Western blotting:

  • Molecular weight verification: Confirm PRKRIP1 detection at the expected molecular weight (~21 kDa)

  • Blocking peptide competition: Pre-incubate antibody with immunizing peptide

  • Multiple antibodies: Validate results using multiple antibodies targeting different PRKRIP1 epitopes

• Immunoprecipitation controls:

  • Input control: Include whole lysate to ensure western blot is working properly

  • Isotype control: Use matched IgG subclass (e.g., Normal Rabbit IgG for rabbit polyclonal)

  • Bead-only control: Include beads without antibody to assess non-specific binding

• Additional validation approaches:

  • Orthogonal testing: Validate antibody results with independent methods (e.g., mRNA detection)

  • Cross-reactivity assessment: Test antibody against related proteins

  • Peptide array analysis: Determine exact epitope binding specificity

What recent advances have been made in PRKRIP1 research using antibodies?

Recent advances in PRKRIP1 research using antibodies have revealed several important findings:

• Biomarker discovery in kidney disease:

  • PRKRIP1 has emerged as a novel autoantigen in chronic kidney disease

  • Anti-PRKRIP1 autoantibodies were significantly elevated in patients with renal insufficiency compared to healthy controls

  • These autoantibodies show promise as biomarkers for tracking CKD progression and potentially predicting disease outcomes

• Correlation with other biomarkers:

  • Anti-PRKRIP1 and anti-angiotensinogen (anti-AGT) levels demonstrated strong correlation across samples with chronic renal injury (Pearson correlation 0.47, p-value 0.00056)

  • This correlation suggests potential mechanistic relationships between these biomarkers and disease pathways

• Improved antibody development methodologies:

  • Development of highly specific monoclonal and polyclonal antibodies targeting different epitopes of PRKRIP1

  • Antibodies now available with reactivity across multiple species (human, mouse, rat, cow, dog, etc.), enabling comparative studies

  • Enhanced validation protocols establishing antibody specificity and performance characteristics

• Application in protein microarray technology:

  • PRKRIP1 antibodies have been successfully incorporated into protein microarray platforms

  • These microarrays contain thousands of proteins printed in duplicate with N-terminal glutathione S transferase (GST) epitopes

  • Such platforms enable high-throughput screening for autoantibodies and protein-protein interactions

How are PRKRIP1 antibodies being used in emerging research areas?

PRKRIP1 antibodies are finding applications in several emerging research areas:

• Chronic disease biomarker development:

  • Beyond kidney disease, researchers are investigating PRKRIP1 as a potential biomarker in other chronic conditions

  • The approach involves screening for novel autoantibodies in various diseases not commonly considered autoimmune

  • This methodology applies the hypothesis that proteins released during end-organ damage may trigger adaptive immune responses detectable in blood

• Integration with advanced proteomics:

  • PRKRIP1 antibodies are being used in conjunction with mass spectrometry to identify post-translational modifications

  • Both bottom-up proteomic workflows for peptide sequencing and top-down LC-MS methods are being employed

  • These approaches help monitor intact mass and identify modifications like phosphorylation or truncation

• Novel antibody design technologies:

  • Recent advances like FlowDesign represent new approaches for sequence-structure co-design for antibodies

  • These methodologies offer flexible selection of prior distributions, direct matching of discrete distributions, and enhanced computational efficiency for large-scale sampling

  • While not specifically targeting PRKRIP1, these technologies could enhance future PRKRIP1 antibody development

• Therapeutic antibody development:

  • Research on antibodies targeting molecules like angiotensinogen demonstrates the potential for therapeutic applications

  • Similar approaches could potentially be applied to PRKRIP1-related pathways

  • Active immunization strategies and therapeutic antibodies may emerge from ongoing research

What are the current limitations of PRKRIP1 antibodies and how might they be addressed in future research?

Current limitations of PRKRIP1 antibodies and potential future solutions include:

• Epitope specificity challenges:

  • Current limitation: Inability to distinguish between full-length PRKRIP1 and specific fragments or epitopes

  • Future solution: Development of more detailed antibody assays to test whether antibodies target full-length protein or specific fragments/epitopes

  • Methodological approach: Epitope mapping using peptide arrays or hydrogen-deuterium exchange mass spectrometry

• Sensitivity and specificity for clinical applications:

  • Current limitation: In pilot studies, anti-PRKRIP1 demonstrated insufficient sensitivity and specificity for clinical use

  • Future solution: Improvements in assays, including further delineation of reactive peptides, to achieve sensitivity and specificity above 90%

  • Methodological approach: Development of high-affinity monoclonal antibodies against specific immunogenic epitopes

• Cross-reactivity with related proteins:

  • Current limitation: Potential cross-reactivity with proteins containing similar epitopes

  • Future solution: Enhanced antibody validation protocols including testing against similar proteins

  • Methodological approach: Comprehensive specificity testing using protein arrays and knockout validation

• Limited understanding of PRKRIP1 function:

  • Current limitation: Incomplete knowledge of PRKRIP1 function limits interpretation of antibody-based studies

  • Future solution: Integration of antibody-based detection with functional studies

  • Methodological approach: Combination of immunoprecipitation with proteomics and interactome analysis

• Technical challenges in standardization:

  • Current limitation: Variability between antibody lots and detection protocols

  • Future solution: Development of recombinant antibodies with consistent properties

  • Methodological approach: Implementation of standardized validation protocols and reference materials for PRKRIP1 detection